Research spinoff ReXceptor gets license for Alzheimer's treatment

April 25, 2013, Case Western Reserve University

Case Western Reserve's Technology Transfer Office has granted an exclusive license of a novel Alzheimer's Disease (AD) treatment strategy to spinoff company ReXceptor Inc., which plans to initiate early-stage human clinical trials of the medication within the next few months.

Gary Landreth, PhD, the Riuko and Archie G. Co Professor of Neurosciences, and his then-graduate student, Paige Cramer, PhD, co-founded ReXceptor after discovering that bexarotene (a medication trademarked as Targretin) reversed AD symptoms in mice within 72 hours of a single dose of treatment. Published last year in the journal Science, their results drew international interest, including stories in the and on .

The U.S. originally approved bexarotene for the treatment of cutaneous T-cell lymphomas—a form of —in 1999. But Landreth, director of the medical school's Alzheimer's Research Laboratory, Cramer and their colleagues found that the medication significantly clears amyloid beta, a protein implicated in the development of Alzheimer's disease when it accumulates in the brain.

The researchers demonstrated that a dose of bexarotene (a retinoid X receptor (RXR) agonist) clears amyloid beta build-up by 25 percent within six hours, an effect that lasted for up to three days. Cognitively impaired mice resumed normal behaviors (demonstrating a restored sense of smell and instinctive interest in nest-building) within 72 hours of receiving the drug.

More than 5.4 million Americans suffer from Alzheimer's disease today, and that figure is expected to more than triple by the year 2050. Translating Case Western Reserve's groundbreaking research into a treatment available for patients is a complex process, but the researchers have great hope for the promise of their approach.

The first stage of testing will involve healthy volunteers, explained Michael Haag, the university's interim director of technology management and the for ReXceptor. Essentially, the researchers hope to prove that the medication acts on amyloid beta in the human brain in a manner similar to the one observed in animal studies. In lay terms, bexarotene functions as a kind of chaperone that escorts the problematic protein out of the cerebral area.

"This is an important proof-of-mechanism study that is a prerequisite for subsequent clinical evaluation of this drug in Alzheimer's patients," Landreth explained.

To date ReXceptor has secured $1.4 million to advance its work. This support includes a landmark collaboration between the Alzheimer's Drug Discovery Foundation and the BrightFocus Foundation to fund early-stage research. The arrangement includes The Charles Evans Foundation/Alzheimer's Drug Discovery Award to ReXceptor of $500,000 and a $250,000 contribution from BrightFocus to the collaboration with ADDF. The company also received two anonymous investments totaling $450,000, and $200,000 from Case Western Reserve.

This new funding has allowed ReXceptor to enter into a formal partnership with C2N Diagnostics, which will assist the company with the initiation and coordination of the clinical trial. C2N Diagnostics will provide its proprietary stable isotope labeling (SILK) platform to measure the metabolism of both brain-derived amyloid beta and apolipoprotein E in the human clinical study.

Haag credited the university's Office of Research and Technology Management, along with the medical school's chief translational officers and Council to Advance Human Health, with providing critical guidance and support in bringing the company to this stage.

Explore further: FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice

Related Stories

FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice

February 9, 2012
Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, ...

Early sign of Alzheimer's reversed in lab

November 30, 2011
One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell – can be restored by removing a plaque-forming protein in a mouse model of the disease, a study led by a Case Western Reserve ...

News of plaque-clearing drug tops week of major advances against Alzheimer's disease

February 10, 2012
In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease. At the same time, the White House and members of Congress are proposing increases in Alzheimer's research ...

Drugs targeting blood vessels may be candidates for treating Alzheimer's

March 7, 2013
(Medical Xpress)—University of British Columbia researchers have successfully normalized the production of blood vessels in the brain of mice with Alzheimer's disease (AD) by immunizing them with amyloid beta, a protein ...

Recommended for you

Energy storehouses in the brain may be source of Alzheimer's, targets of new therapy

January 23, 2018
Alzheimer's disease, a severely debilitating and ultimately fatal brain disorder, affects millions worldwide. To date, clinical efforts to find a cure or adequate treatment have met with dispiriting failure.

Rocky start for Alzheimer's drug research in 2018

January 19, 2018
The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.